About 40%-70%of the patients with treatment-resistant schizophrenia have a poor response to adequate treatment with clozapine.The impact of clozapineresistant schizophrenia(CRS)is even greater than that of treatment r...About 40%-70%of the patients with treatment-resistant schizophrenia have a poor response to adequate treatment with clozapine.The impact of clozapineresistant schizophrenia(CRS)is even greater than that of treatment resistance in terms of severe and persistent symptoms,relapses and hospitalizations,poorer quality of life,and healthcare costs.Such serious consequences often compel clinicians to try different augmentation strategies to enhance the inadequate clozapine response in CRS.Unfortunately,a large body of evidence has shown that antipsychotics,antidepressants,mood stabilizers,electroconvulsive therapy,and cognitive-behavioural therapy are mostly ineffective in augmenting clozapine response.When beneficial effects of augmentation have been found,they are usually small and of doubtful clinical significance or based on low-quality evidence.Therefore,newer treatment approaches that go beyond the evidence are needed.The options proposed include developing a clinical consensus about the augmentation strategies that are most likely to be effective and using them sequentially in patients with CRS.Secondly,newer approaches such as augmentation with long-acting antipsychotic injections or multi-component psychosocial interventions could be considered.Lastly,perhaps the most effective way to deal with CRS would be to optimize clozapine treatment,which might prevent clozapine resistance from developing.Personalized dosing,adequate treatment durations,management of side effects and non-adherence,collaboration with patients and caregivers,and addressing clinician barriers to clozapine use are the principal ways of ensuring optimal clozapine treatment.At present,these three options could the best way to manage CRS until research provides more firm directions about the effective options for augmenting clozapine response.展开更多
文摘About 40%-70%of the patients with treatment-resistant schizophrenia have a poor response to adequate treatment with clozapine.The impact of clozapineresistant schizophrenia(CRS)is even greater than that of treatment resistance in terms of severe and persistent symptoms,relapses and hospitalizations,poorer quality of life,and healthcare costs.Such serious consequences often compel clinicians to try different augmentation strategies to enhance the inadequate clozapine response in CRS.Unfortunately,a large body of evidence has shown that antipsychotics,antidepressants,mood stabilizers,electroconvulsive therapy,and cognitive-behavioural therapy are mostly ineffective in augmenting clozapine response.When beneficial effects of augmentation have been found,they are usually small and of doubtful clinical significance or based on low-quality evidence.Therefore,newer treatment approaches that go beyond the evidence are needed.The options proposed include developing a clinical consensus about the augmentation strategies that are most likely to be effective and using them sequentially in patients with CRS.Secondly,newer approaches such as augmentation with long-acting antipsychotic injections or multi-component psychosocial interventions could be considered.Lastly,perhaps the most effective way to deal with CRS would be to optimize clozapine treatment,which might prevent clozapine resistance from developing.Personalized dosing,adequate treatment durations,management of side effects and non-adherence,collaboration with patients and caregivers,and addressing clinician barriers to clozapine use are the principal ways of ensuring optimal clozapine treatment.At present,these three options could the best way to manage CRS until research provides more firm directions about the effective options for augmenting clozapine response.
